首页> 外文期刊>Chemotherapy Research and Practice >Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
【24h】

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

机译:NSCLC患者对表皮生长因子受体抑制剂的耐药机制和克服耐药性的新治疗策略

获取原文
           

摘要

The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI treatment is not curative in patients because of both primary and secondary treatment resistance. Studies over the last decade have identified mechanisms that drive primary and secondary resistance to EGFR TKI treatment. The elucidation of mechanisms of resistance to EGFR TKI treatment provides a basis for the development of therapeutic strategies to overcome resistance and enhance outcomes in NSCLC patients. In this paper, we summarize the mechanisms of resistance to EGFR TKIs that have been identified to date and discusses potential therapeutic strategies to overcome EGFR TKI resistance in NSCLC patients.
机译:表皮生长因子受体(EGFR)是特征明确的致癌基因,通常在非小细胞肺癌(NSCLC)中被体细胞激酶结构域突变激活。 EGFR TKIs对于肿瘤带有EGFR激活突变的NSCLC患者是有效的疗法。但是,由于主要和次要治疗均耐药,EGFR TKI治疗不能治愈患者。过去十年的研究已经确定了导致对EGFR TKI治疗产生主要和次要耐药性的机制。对EGFR TKI治疗的耐药机制的阐明为开发克服NSCLC患者的耐药性并增强预后的治疗策略提供了基础。在本文中,我们总结了迄今已确定的对EGFR TKI耐药的机制,并讨论了克服NSCLC患者的EGFR TKI耐药的潜在治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号